You are here: Industry Insights > Market News > Botswana: AstraZeneca Vaccines Arrives in Botswana

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Botswana: AstraZeneca Vaccines Arrives in Botswana

firstwordpharmaAugust 09, 2021

Tag: Botswana , AstraZeneca , Vaccine

Favorites

Government of Botswana this afternoon received 38 400 doses of the AstraZeneca vaccine. The consignment has been purchased by the government through the COVAX facility. Part of this consignment will be used as second dose for those who were previously informed that their second doses were not available. According to a press statement from the Ministry of Health and Wellness, District Health Management Teams (DHMTs) across the country will advise all those concerned in their respective areas, on when they could come for their second dose.

Previous:Three Lakes Foundation, Lung Foundation Australia and Centre of Research Excellence in PF join forces to create a global network for PF research

Next:Additional COVID-19 treatment for Australia

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

PharmaSourcesMay 16, 2024

InnoCare announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, for the treatment of psoriasis.

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Biotech NewswireMay 14, 2024

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

Biotech NewswireMay 10, 2024

Botswana: AstraZeneca Vaccines Arrives in Botswana | Pharmasources.com

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

Biotech NewswireMay 09, 2024

The first commercial manufacturing run of LYFGENIA – a one-time gene therapy for the treatment of sickle cell disease developed by bluebird bio – was performed at its Allendale, NJ site.

Botswana: AstraZeneca Vaccines Arrives in Botswana

Related News

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

You may like